Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Files
Publication date
2021-08-01
Authors
van den Bent, Martin
Eoli, Marica
Sepulveda, Juan Manuel
Smits, Marion
Walenkamp, Annemiek
Frenel, Jean-Sebastian
Franceschi, Enrico
Clement, Paul M
Chinot, Olivier
de Vos, Filip Y F L
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
Abstract
Corrigendum to Bent et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol (doi: 10.1093/neuonc/noz222) first published online November 20, 2019. In table 2, the rows in the hematology and investigation sections were misplaced one line. This has been corrected.
Keywords
Clinical Neurology, Oncology, Cancer Research, Journal Article
Citation
van den Bent, M, Eoli, M, Sepulveda, J M, Smits, M, Walenkamp, A, Frenel, J-S, Franceschi, E, Clement, P M, Chinot, O, de Vos, F, Whenham, N, Sanghera, P, Weller, M, Dubbink, H J, French, P, Looman, J, Dey, J, Krause, S, Ansell, P, Nuyens, S, Spruyt, M, Brilhante, J, Coens, C, Gorlia, T & Golfinopoulos, V 2021, 'Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma', Neuro-Oncology, vol. 23, no. 8, pp. 1415-1415. https://doi.org/10.1093/neuonc/noaa115